EirGenix

EirGenix Equity

The The Equity of EirGenix (6589.TWO) as of Oct 17, 2026 is 8.34 B TWD. In the previous year, The Equity was 9.26 B TWD — a change of -9.90% (lower).

Equity

8.34 BTWD

YoY

-9.90%

Last updated:

In 2025, EirGenix's equity was 8.34 B TWD, a -9.90% increase from the 9.26 B TWD equity in the previous year.

The EirGenix Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2018
2.09 B TWD
Jan 1, 2019
1.85 B TWD
Jan 1, 2020
1.91 B TWD
Jan 1, 2021
10.43 B TWD
Jan 1, 2022
10.68 B TWD
Jan 1, 2023
10.02 B TWD
Jan 1, 2024
9.26 B TWD
Jan 1, 2025
8.34 B TWD
The EirGenix Equity history
YEAREquityYoY
8.34 BTWD-9.90%
9.26 BTWD-7.58%
10.02 BTWD-6.23%
10.68 BTWD+2.44%
10.43 BTWD+447.26%
1.91 BTWD+2.74%
1.85 BTWD-11.15%
2.09 BTWD+82.36%
1.14 BTWD-12.32%
1.31 BTWD+85.05%
705.56 MTWD-12.77%
808.87 MTWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

EirGenix Stock analysis

What does EirGenix do? EirGenix Inc., headquartered in Taipei, Taiwan, operates in the Health Care sector within the Life Sciences Tools & Services industry. The company provides Contract Development & Manufacturing Organization (CDMO) services, including cell strain construction, clinical trial medicine manufacturing, analytical science, protein identification, and PIC/S-compliant manufacturing facilities for clinical trial drug production. Listed on 23 November 2016, EirGenix employs 170 people and focuses on biotechnology drug research and development. EirGenix is one of the most popular companies on Eulerpool.

Equity Details

Analyzing EirGenix's Equity

EirGenix's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding EirGenix's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating EirGenix's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

EirGenix's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in EirGenix’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about EirGenix stock

The Equity of EirGenix is 8.34 B TWD in 2025.

The Equity of EirGenix changed from 9.26 B TWD to 8.34 B TWD, representing a -9.90% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity EirGenix since 2006 – with annual values, charts, and detailed analysis.

The Equity's TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's EirGenix historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — EirGenix

All Key Metrics — EirGenix